Jyong Biotech Ltd. MENS 深 沪
等待开盘 07-02 09:30:00 美东时间
2.05
-0.020
-0.97%
华盛通- 最 高2.2999
- 今 开2.09
- 成交量 5.67万股
- 最 低 2.01
- 昨 收 2.07
- 总市值 1.56亿
- 52周最高 67.00
- 市盈率 静 --
- 换手率 0.07%
- 52周最低 1.43
- 委 比 33.33%
- 总股本 7602.77万
- 历史最高 67.00
- 量 比 0.26
- 振 幅 14.00%
- 历史最低 1.43
- 每 手 1
- 风险率 21.39%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview
Jyong Biotech Ltd., a biotechnology company, highlights its strategic vision to develop innovative plant-derived therapeutics. CEO Fu-Feng Kuo emphasizes the Company’s hybrid operating model, combining Taiwanese R&D with US regulatory expertise to meet FDA standards. The Company’s proprietary chylomicron and micelle technologies enhance drug bioavailability, with invention patents across the US, EU, and Asia. Its lead asset, Botreso® for benign p...
05-29 12:00
Jyong Biotech FY25 net loss widens 55% to US$4.67 million
Jyong Biotech FY25 net loss widens 55% to US$4.67 million Jyong Biotech posted a net loss of US $4.67 million, widening from US $3.02 million a year earlier. Operating loss widened to US $2.61 million as total operating expenses rose 27% to US $2.61 million. General and administrative costs climbed
05-15 18:19
Jyong Biotech Delays Annual 20-F (Yearly Report)
Jyong Biotech Ltd. ( ($MENS) ) has released a notification of late filing. Jyon...
04-30 02:19
Jyong Biotech Advances Market Access Strategies For Its Plant-Based Drugs Botreso And PCP After Analysis Of Their Clinical Efficacy And Competitive Advantages
As previously announced, its first core product, Botreso®, has completed four Phase III clinical trials (API-1) in the United States and Taiwan while its second core product, PCP, has successfully completed its
04-28 20:37
Jyong Biotech updates MCS-2 BPH/LUTS program; Phase III trials span 27 U.S. centers in 19 states
Jyong Biotech updates MCS-2 BPH/LUTS program; Phase III trials span 27 U.S. centers in 19 states Jyong Biotech reported updated information on MCS-2, an investigational oral botanical drug candidate being studied for benign prostatic hyperplasia/lower urinary tract symptoms. The company said MCS-2 h
03-27 20:30
Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2
Jyong Biotech Ltd., a biotechnology company based in Taiwan, has provided updates on MCS-2, an innovative plant-derived drug developed to treat benign prostatic hyperplasia and lower urinary tract symptoms (BPH/LUTS). MCS-2 is the first oral botanical drug globally to complete Phase III clinical trials, with data from trials showing excellent safety and no serious adverse events. The company believes MCS-2 addresses the unmet need for a safe, lon...
03-27 12:30
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers CASI Pharmaceuticals (NASDAQ:CASI) shares rose 54.2% to $0.32 during W...
02-26 05:07
Jyong Biotech Completes Phase II Trial For MCS-8, Expands Commercial Presence In Asia
- Comprehensive review of recent milestones highlights statistically significant efficacy in prostate cancer prevention, discovery of novel lipid-modulating properties, and the execution of high-value commercial
02-12 21:55
Jyong Biotech Announces Updated Statistical Analyses For Key Blood Biochemical Markers From Phase II Clinical Trial Of MCS-8 Conducted In Taiwan
Jyong Biotech Ltd. (NASDAQ:MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs
01-30 21:45
Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value
Jyong Biotech Ltd. announced updated results from its Phase II clinical trial of MCS-8 (PCP), showing its potential in prostate cancer prevention and reducing high-grade malignancy risk. The trial demonstrated improved lipid control, including a significant reduction in total cholesterol and no increase in LDH levels in the MCS-8 group, suggesting no cell damage. Safety data indicated long-term use did not increase adverse events. The company pla...
01-30 13:30
